Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Cade, W Todd ^a   Reeds, Dominic N ^a   Overton, E Turner ^a   Herrero, Pilar ^a   Waggoner, Alan D ^a   Davila Roman, Victor G ^a   Lassa Claxton, Sherry ^a   Gropler, Robert J ^a   Soto, Pablo F ^a   Krauss, Melissa J ^a   Yarasheski, Kevin E ^a   Peterson, Linda R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac metabolism and function; Insulin resistance; Pet imaging

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBON 11; FATTY ACID; GLUCOSE; INSULIN; PALMITIC ACID; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD FLOW; BODY COMPOSITION; DIASTOLE; ECHOCARDIOGRAPHY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE METABOLISM; HEART MUSCLE RELAXATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; MITOCHONDRION; NUTRIENT; OXYGEN CONSUMPTION; POSITRON EMISSION TOMOGRAPHY; ANALYSIS OF VARIANCE; BLOOD; CORONARY ARTERY BLOOD FLOW; CROSS-SECTIONAL STUDY; ENERGY METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; UNITED STATES;

ADULT; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CORONARY CIRCULATION; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; ENERGY METABOLISM; FATTY ACIDS; GLUCOSE; HIV INFECTIONS; HUMANS; INSULIN; INSULIN RESISTANCE; LINEAR MODELS; MALE; METABOLIC DISEASES; MIDDLE AGED; MISSOURI; MULTIVARIATE ANALYSIS; MYOCARDIUM; OXYGEN CONSUMPTION; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 82955246760     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-111     Document Type: Article

References (72)

1. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000, 31(3):787-797. 10.1086/313995, 11017831.
2. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349(21):1993-2003.
3. Cade WT. Left ventricular dysfunction in human immunodeficiency virus infection. J Cardiometab Syndr 2008, 3(2):83-87. 10.1111/j.1559-4572.2008.07581.x, 18453807.
4. Meng Q, Lima JA, Lai H, Vlahov D, Celentano DD, Strathdee S, Nelson KE, Tong W, Lai S. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. J Acquir Immune Defic Syndr 2002, 30(3):306-310.
5. Hsue PY, Hunt PW, Ho JE, Farah HH, Schnell A, Hoh R, Martin JN, Deeks SG, Bolger AF. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 2010, 3(1):132-139. 10.1161/CIRCHEARTFAILURE.109.854943, 2837081, 19933410.
6. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia J. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis 2003, 37(10):1365-1373. 10.1086/379077, 14583871.
7. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86(1):27-31. 10.1016/0002-9343(89)90225-8, 2653028.
8. Richmond SR, Carper MJ, Lei X, Zhang S, Yarasheski KE, Ramanadham S. HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters. Biochim Biophys Acta 2010, 1801(5):559-566. 2838954, 20117238.
9. Dimock D, Thomas V, Cushing A, Purdy JB, Worrell C, Kopp JB, Hazra R, Hadigan C. Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood. Metabolism 2011, 60(6):874-880. 10.1016/j.metabol.2010.08.007, 20947103.
10. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12(7):F51-58. 10.1097/00002030-199807000-00003, 9619798.
11. Schmidt HH, Behrens G, Genschel J, Stoll M, Dejam A, Haas R, Manns MP, Schmidt RE. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors. Antivir Ther 1999, 4(3):163-170.
12. Bernal E, Masia M, Padilla S, Gutierrez F. High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDS 2008, 22(7):569-575. 10.1089/apc.2007.0186, 18479224.
13. Reeds DN, Yarasheski KE, Fontana L, Cade WT, Laciny E, DeMoss A, Patterson BW, Powderly WG, Klein S. Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab 2006, 290(1):E47-E53.
14. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, Halban PA, Cryer PE, Powderly WG. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999, 21(3):209-216. 10.1097/00126334-199907010-00005, 3182110, 10421244.
15. Calza L, Masetti G, Piergentili B, Trapani F, Cascavilla A, Manfredi R, Colangeli V, Viale P. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS 2011, 22(1):43-45. 10.1258/ijsa.2010.010256, 21364066.
16. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006, 20(7):1019-1026. 10.1097/01.aids.0000222074.45372.00, 16603854.
17. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32(1):130-139. 10.1086/317541, 11118392.
18. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765.
19. Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011, 11:40. 10.1186/1471-2334-11-40, 3042932, 21294867.
20. Troseid M, Seljeflot I, Arnesen H. The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol 2010, 9:11. 10.1186/1475-2840-9-11, 2858122, 20331890.
21. Azevedo A, Bettencourt P, Almeida PB, Santos AC, Abreu-Lima C, Hense HW, Barros H. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities--cross-sectional study of the general population. BMC Cardiovasc Disord 2007, 7:17. 10.1186/1471-2261-7-17, 1894986, 17555566.
22. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, Gropler RJ. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006, 47(3):598-604. 10.1016/j.jacc.2005.09.030, 16458143.
23. Peterson LR, Herrero P, McGill J, Schechtman KB, Kisrieva-Ware Z, Lesniak D, Gropler RJ. Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes. Diabetes 2008, 57(1):32-40.
24. Herrero P, McGill J, Lesniak DS, Dence CS, Scott SW, Kisrieva-Ware Z, Gropler RJ. PET detection of the impact of dobutamine on myocardial glucose metabolism in women with type 1 diabetes mellitus. J Nucl Cardiol 2008, 15(6):791-799. 2871775, 18984454.
25. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002, 51(10):3020-3024. 10.2337/diabetes.51.10.3020, 12351442.
26. Jagasia D, Whiting JM, Concato J, Pfau S, McNulty PH. Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 2001, 103(13):1734-1739.
27. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004, 109(18):2191-2196. 10.1161/01.CIR.0000127959.28627.F8, 15123530.
28. Peterson LR, Soto PF, Herrero P, Mohammed BS, Avidan MS, Schechtman KB, Dence C, Gropler RJ. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc Imaging 2008, 1(4):424-433. 10.1016/j.jcmg.2008.05.004, 2982260, 19356462.
29. Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, Bienstock RJ, Ludaway T, McNaught J, Russ R, Stuart T, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 2006, 20(5):675-684. 10.1097/01.aids.0000216367.23325.58, 1779943, 16514297.
30. Carper MJ, Cade WT, Cam M, Zhang S, Shalev A, Yarasheski KE, Ramanadham S. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2008, 294(3):E558-567. 10.1152/ajpendo.00167.2007, 18171911.
31. Nolte LA, Yarasheski KE, Kawanaka K, Fisher J, Le N, Holloszy JO. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001, 50(6):1397-1401. 10.2337/diabetes.50.6.1397, 11375341.
32. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000, 49(5):677-683. 10.2337/diabetes.49.5.677, 10905472.
33. Oakes ND, Thalen P, Aasum E, Edgley A, Larsen T, Furler SM, Ljung B, Severson D. Cardiac metabolism in mice: tracer method developments and in vivo application revealing profound metabolic inflexibility in diabetes. Am J Physiol Endocrinol Metab 2006, 290(5):E870-881. 10.1152/ajpendo.00233.2005, 16352676.
34. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000, 279(5):E1104-1113.
35. How OJ, Larsen TS, Hafstad AD, Khalid A, Myhre ES, Murray AJ, Boardman NT, Cole M, Clarke K, Severson DL, et al. Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch Physiol Biochem 2007, 113(4-5):211-220. 10.1080/13813450701783281, 18158644.
36. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI, Bugger H, Zaha VG, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007, 56(10):2457-2466. 10.2337/db07-0481, 17623815.
37. Tian R, Nascimben L, Ingwall JS, Lorell BH. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 1997, 96(4):1313-1319.
38. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, Levy D, Redfield MM, Pieske BM, Benjamin EJ, et al. Cardiac Dysfunction and Noncardiac Dysfunction as Precursors of Heart Failure With Reduced and Preserved Ejection Fraction in the Community. Circulation 2011, 124(1):24-30. 10.1161/CIRCULATIONAHA.110.979203, 21670229.
39. Cave AC, Ingwall JS, Friedrich J, Liao R, Saupe KW, Apstein CS, Eberli FR. ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate. Circulation 2000, 101(17):2090-2096.
40. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007, 115(25):3213-3223. 10.1161/CIRCULATIONAHA.106.679597, 17592090.
41. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997, 126(4):296-306.
42. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007, 44(5):726-734. 10.1086/511679, 3170426, 17278068.
43. Young ME, Razeghi P, Cedars AM, Guthrie PH, Taegtmeyer H. Intrinsic diurnal variations in cardiac metabolism and contractile function. Circ Res 2001, 89(12):1199-1208. 10.1161/hh2401.100741, 11739286.
44. Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol 1989, 14(3):639-652. 10.1016/0735-1097(89)90105-8, 2788669.
45. Herrero P, Weinheimer CJ, Dence C, Oellerich WF, Gropler RJ. Quantification of myocardial glucose utilization by PET and 1-carbon-11-glucose. J Nucl Cardiol 2002, 9(1):5-14. 10.1067/mnc.2001.120635, 11845124.
46. Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 1996, 37(10):1723-1730.
47. Buck A, Wolpers HG, Hutchins GD, Savas V, Mangner TJ, Nguyen N, Schwaiger M. Effect of carbon-11-acetate recirculation on estimates of myocardial oxygen consumption by PET. J Nucl Med 1991, 32(10):1950-1957.
48. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18(12):1440-1463. 10.1016/j.echo.2005.10.005, 16376782.
49. Lansang MC, Williams GH, Carroll JS. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens 2001, 14:51-53. 10.1016/S0895-7061(00)01229-2, 11206679.
50. Yarasheski KE, Tebas P, Claxton S, Marin D, Coleman T, Powderly WG, Semenkovich CF. Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia. Am J Physiol Endocrinol Metab 2003, 285(4):E899-905.
51. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009, 338:a3172. 10.1136/bmj.a3172, 19171560.
52. Taylor SA, Lee GA, Pao VY, Anthonypillai J, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr 2010, 55(3):361-364. 10.1097/QAI.0b013e3181e6a7d9, 3164483, 20595906.
53. Stanley TL, Joy T, Hadigan CM, Liebau JG, Makimura H, Chen CY, Thomas BJ, Weise SB, Robbins GK, Grinspoon SK. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 2009, 23(11):1349-1357. 10.1097/QAD.0b013e32832ba904, 2886977, 19474651.
54. Dube MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis 2008, 47(4):567-574. 10.1086/590154, 2919310, 18636958.
55. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003, 107(24):3040-3046. 10.1161/01.CIR.0000072789.89096.10, 12810608.
56. Hafstad AD, Khalid AM, How OJ, Larsen TS, Aasum E. Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2007, 292(5):E1288-1294. 10.1152/ajpendo.00504.2006, 17213470.
57. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 1974, 36:413-459. 10.1146/annurev.ph.36.030174.002213, 19400669.
58. Serraino D, Bruzzone S, Zucchetta A, Suligoi B, De Paoli A, Pennazza S, Camoni L, Dal Maso L, De Paoli P, Rezza G. Elevated risks of death for diabetes mellitus and cardiovascular diseases in Italian AIDS cases. AIDS Research and Therapy 2010, 7(11).
59. Hsue PY, Hunt PW, Ho JE, Farah HH, Schnell A, Hoh R, Martin JN, Deeks SG, Bolger AF. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 2010, 3(1):132-139. 10.1161/CIRCHEARTFAILURE.109.854943, 2837081, 19933410.
60. Thoni GJ, Schuster I, Walther G, Nottin S, Vinet A, Boccara F, Mauboussin JM, Rouanet I, Ederhy S, Dauzat M, et al. Silent cardiac dysfunction and exercise intolerance in HIV+ men receiving combined antiretroviral therapies. AIDS 2008, 22(18):2537-2540. 10.1097/QAD.0b013e328319806d, 19005278.
61. Coudray N, de Zuttere D, Force G, Champetier de Ribes D, Pourny JC, Antony I, Lecarpentier Y, Chemla D. Left ventricular diastolic function in asymptomatic and symptomatic human immunodeficiency virus carriers: an echocardiographic study. Eur Heart J 1995, 16(1):61-67. 10.1093/eurheartj/16.1.61, 7737224.
62. Martinez-Garcia T, Sobrino JM, Pujol E, Galvez J, Benitez E, Giron-Gonzalez JA. Ventricular mass and diastolic function in patients infected by the human immunodeficiency virus. Heart 2000, 84(6):620-624. 10.1136/heart.84.6.620, 1729508, 11083740.
63. Gong HP, Tan HW, Fang NN, Song T, Li SH, Zhong M, Zhang W, Zhang Y. Impaired left ventricular systolic and diastolic function in patients with metabolic syndrome as assessed by strain and strain rate imaging. Diabetes Res Clin Pract 2009, 83(3):300-307. 10.1016/j.diabres.2008.10.018, 19167773.
64. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000, 101(8):899-907.
65. Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol 1983, 244(6):E528-535.
66. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008, 117(1):43-51. 10.1161/CIRCULATIONAHA.107.728550, 18071071.
67. Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, Davila-Roman VG. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 2004, 43(8):1399-1404. 10.1016/j.jacc.2003.10.062, 15093874.
68. de las Fuentes L, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler RJ, Davila-Roman VG. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J 2007, 28(5):553-559.
69. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419. 10.1007/BF00280883, 3899825.
70. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23(1):57-63. 10.2337/diacare.23.1.57, 10857969.
71. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009, 54(16):1524-1532. 10.1016/j.jacc.2009.04.074, 19815124.
72. Soto PF, Herrero P, Schechtman KB, Waggoner AD, Baumstark JM, Ehsani AA, Gropler RJ. Exercise training impacts the myocardial metabolism of older individuals in a gender-specific manner. Am J Physiol Heart Circ Physiol 2008, 295(2):H842-850. 10.1152/ajpheart.91426.2007, 2519215, 18567700.